Almstead Neil Gregory 4

What Happened
Neil Gregory Almstead, Chief Technical Operations Officer at PTC Therapeutics (PTCT), exercised 2,464 stock options and immediately sold the resulting 2,464 shares on July 9, 2026. The options were exercised at $46.54 per share (total cash cost $114,675), and the shares were sold in the open market at a weighted average price of $90.25 per share for total proceeds of approximately $222,376. The filing shows the option conversion/disposition entry at $0.00, reflecting the conversion of the derivative into shares and subsequent sale.

Key Details

• Transaction date: July 9, 2026.
• Exercise: 2,464 shares at $46.54 each = $114,675 (Form 4 code M).
• Sale: 2,464 shares at weighted avg $90.25 each = $222,376 (Form 4 code S). Sales executed at prices between $90.00 and $90.70 (see footnote F2).
• Plan/authorization: Sales were effected pursuant to a written Rule 10b5-1 trading plan adopted Nov 11, 2025 (footnote F1).
• Option grant/vesting: Option granted Jan 3, 2025; vests 25% on Jan 3, 2026 and 6.25% each quarter thereafter (footnote F3).
• Shares owned after transaction: Not disclosed in the provided filing.
• Filing timeliness: Reported on July 13, 2026; filed within the SEC two-business-day reporting window for the July 9 transaction.

Context
This was an exercise of vested options followed by an immediate open-market sale (commonly a cashless exercise). The use of a pre-established Rule 10b5-1 plan indicates the sale was executed under a pre-set trading arrangement rather than an ad-hoc decision; footnote F2 indicates multiple trades produced the reported weighted average sale price.